Flavia Biamonte

Mutations and prognosis in primary myelofibrosis

A. M. Vannucchi, T L Lasho, Paola Guglielmelli et al. · Leukemia · 2013 · 739 citations

Hematological Malignancy, Hematology, Pathology +4

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

Paola Guglielmelli, Terra L. Lasho, Giada Rotunno et al. · Leukemia · 2014 · 307 citations

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +9

EZH2 mutational status predicts poor survival in myelofibrosis

Paola Guglielmelli, Flavia Biamonte, Joannah Score et al. · Blood · 2011 · 253 citations · Full text

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

Paola Guglielmelli, Giovanni Barosi, Alessandro Rambaldi et al. · Blood · 2011 · 148 citations · Full text

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study

Paola Guglielmelli, Flavia Biamonte, Giada Rotunno et al. · Blood · 2014 · 126 citations · Full text